Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE - Get Free Report) shares gapped down prior to trading on Friday. The stock had previously closed at $151.02, but opened at $129.00. Belite Bio shares last traded at $128.7930, with a volume of 194,973 shares changing hands.
Analysts Set New Price Targets
A number of research firms recently weighed in on BLTE. Mizuho raised their target price on shares of Belite Bio from $221.00 to $230.00 and gave the company an "outperform" rating in a research report on Monday. Canaccord Genuity Group raised their target price on shares of Belite Bio from $303.00 to $314.00 and gave the stock a "buy" rating in a report on Monday. HC Wainwright restated a "buy" rating and set a $245.00 target price on shares of Belite Bio in a research note on Thursday, October 15th. UBS Group reissued a "buy" rating on shares of Belite Bio in a report on Thursday, September 3rd. Finally, Cantor Fitzgerald lifted their price target on shares of Belite Bio from $266.00 to $270.00 and gave the stock an "overweight" rating in a report on Wednesday, August 12th. Nine equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $226.91.
View Our Latest Analysis on Belite Bio
Belite Bio Price Performance
The firm has a market capitalization of $5.25 billion, a price-to-earnings ratio of -47.82 and a beta of -1.19. The business's fifty day simple moving average is $158.54 and its 200 day simple moving average is $159.99.
Belite Bio (NASDAQ:BLTE - Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.19. Equities research analysts expect that Belite Bio, Inc. Sponsored ADR will post -3.06 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other news, CFO Hao-Yuan Chuang sold 49,433 shares of the stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $187.64, for a total value of $9,275,608.12. Following the completion of the sale, the chief financial officer owned 44,000 shares in the company, valued at $8,256,160. This represents a 52.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Hendrik Scholl sold 2,000 shares of the stock in a transaction dated Thursday, November 12th. The shares were sold at an average price of $165.99, for a total transaction of $331,980.00. Following the completion of the sale, the insider owned 12,500 shares of the company's stock, valued at approximately $2,074,875. This trade represents a 13.79% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 170,330 shares of company stock valued at $32,301,098 in the last three months. 13.29% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Belite Bio
Several large investors have recently modified their holdings of BLTE. Marshall Wace LLP bought a new stake in shares of Belite Bio in the third quarter valued at approximately $15,282,000. Great Point Partners LLC purchased a new position in shares of Belite Bio during the third quarter worth about $12,736,000. Candriam S.C.A. bought a new position in shares of Belite Bio in the 3rd quarter worth $10,711,000. Affinity Asset Advisors LLC raised its position in Belite Bio by 225.0% during the first quarter. Affinity Asset Advisors LLC now owns 65,000 shares of the company's stock valued at $10,364,000 after purchasing an additional 45,000 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new position in shares of Belite Bio during the 1st quarter valued at about $8,291,000. Hedge funds and other institutional investors own 0.53% of the company's stock.
About Belite Bio
(
Get Free Report)
Belite Bio, Inc. is a clinical-stage biopharmaceutical company developing treatments for retinal and metabolic diseases. The company focuses on conditions with limited treatment options, including inherited retinal disorders and age-related eye disease. Its lead drug candidate, tinlarebant, is an oral therapy designed to reduce the accumulation of toxic vitamin A byproducts in the retina. Belite Bio is evaluating tinlarebant for Stargardt disease and geographic atrophy associated with dry age-related macular degeneration.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Belite Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Belite Bio wasn't on the list.
While Belite Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.